Comprehensive Landscape of HOXA2, HOXA9, and HOXA10 as Potential Biomarkers for Predicting Progression and Prognosis in Prostate Cancer

Prostate cancer (PCa) is recognized as a common malignancy in male patients. The homeobox A cluster (HOXA) family members have been confirmed to be implicated in the development of several types of tumors. However, the expression pattern and prognostic values of HOXA genes in PCa have not been investigated. In this study, we analyzed TCGA datasets and identified six HOXA family members which showed a dysregulated expression in PCa specimens compared with nontumor specimens. We also explored the potential mechanisms involved in the dysregulation of HOXA family members in PCa, and the results of Pearson's correlation revealed that most HOXA members were negatively related to the methylation degree. Moreover, we explored the prognostic values of HOXA family members and identified six survival-related HOXA members. Importantly, HOXA2, HOXA9, and HOXA10 were identified as critical PCa-related genes which were abnormally expressed in PCa and associated with clinical outcomes of PCa patients. Then, we explored the association between the above three genes and immune cell infiltration. We observed that the levels of HOXA2, HOXA9, and HOXA10 were associated with the levels of immune infiltration of several kinds of immune cells. Overall, our findings identified the potential values of the HOXA family for outcome prediction in PCa, which might facilitate personalized counselling and treatment in PCa.

[1]  T. Polascik,et al.  Evolution of Focal Therapy in Prostate Cancer: Past, Present, and Future. , 2021, The Urologic clinics of North America.

[2]  Jihong Liu,et al.  Identification of a Ubiquitin Related Genes Signature for Predicting Prognosis of Prostate Cancer , 2022, Frontiers in Genetics.

[3]  A. Ismail,et al.  A review of the biological role of miRNAs in prostate cancer suppression and progression. , 2021, International journal of biological macromolecules.

[4]  B. İnce,et al.  Biosensing strategies for diagnosis of prostate specific antigen. , 2021, Journal of pharmaceutical and biomedical analysis.

[5]  G. Kramer,et al.  The prostate cancer landscape in Europe: Current challenges, future opportunities. , 2021, Cancer letters.

[6]  K. Sengupta,et al.  Nup93 and CTCF modulate spatiotemporal dynamics and function of the HOXA gene locus during differentiation. , 2021, Journal of cell science.

[7]  S. Pramanik,et al.  Epigenetic modifications from arsenic exposure: A comprehensive review. , 2021, The Science of the total environment.

[8]  A. Thompson,et al.  Role of the HOXA cluster in HSC emergence and blood cancer. , 2021, Biochemical Society transactions.

[9]  F. Setién,et al.  Impact of the Epigenetically Regulated Hoxa-5 Gene in Neural Differentiation from Human Adipose-Derived Stem Cells , 2021, Biology.

[10]  M. Landfors,et al.  A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer , 2021, Clinical epigenetics.

[11]  Dongying Wang Promotive effects of HOXA10 antisense RNA on the stemness of oral squamous cell carcinoma stem cells through a microRNA-29a/MCL-1/phosphatidyl inositol 3-kinase/protein kinase B axis. , 2021, Archives of oral biology.

[12]  A. Kishan,et al.  A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). , 2020, European urology.

[13]  Cheng-Chia Yu,et al.  Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development , 2020, International journal of nanomedicine.

[14]  Kaiyu Qian,et al.  Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer , 2020, Cancer medicine.

[15]  B. Cong,et al.  Silencing lncRNA HOXA10-AS decreases cell proliferation of oral cancer and HOXA10-antisense RNA can serve as a novel prognostic predictor , 2020, The Journal of international medical research.

[16]  Han Lin,et al.  The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer. , 2020, Future oncology.

[17]  R. Cao,et al.  Tumour Microenvironment (TME) Characterization Identified Prognosis and Immunotherapy Response in Muscle-Invasive Bladder Cancer (MIBC) , 2019, SSRN Electronic Journal.

[18]  P. Arnaud,et al.  HOX gene cluster (de)regulation in brain: from neurodevelopment to malignant glial tumours , 2020, Cellular and Molecular Life Sciences.

[19]  M. Becerra,et al.  Serum and urine biomarkers for detecting clinically significant prostate cancer. , 2020, Urologic oncology.

[20]  A. Melcher,et al.  Inflammatory microenvironment remodelling by tumour cells after radiotherapy , 2020, Nature Reviews Cancer.

[21]  J. Zhao,et al.  SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer , 2020, Journal of experimental & clinical cancer research : CR.

[22]  C. Stirzaker,et al.  The DNA methylation landscape in cancer , 2019, Essays in biochemistry.

[23]  Yun Wang,et al.  The Role of the HOXA Gene Family in Acute Myeloid Leukemia , 2019, Genes.

[24]  Wanhai Xu,et al.  EGR1 Regulates Angiogenic and Osteoclastogenic Factors in Prostate Cancer and Promotes Metastasis , 2019, Oncogene.

[25]  D. Chan,et al.  Cancer biomarker discovery and translation: proteomics and beyond , 2019, Expert review of proteomics.

[26]  Q. Huang,et al.  HOXA4, down-regulated in lung cancer, inhibits the growth, motility and invasion of lung cancer cells , 2018, Cell Death & Disease.

[27]  Adrienne Morgan,et al.  Review of systematic reviews of non-pharmacological interventions to improve quality of life in cancer survivors , 2017, BMJ Open.

[28]  Ying Cai,et al.  HOXA13 is associated with unfavorable survival and acts as a novel oncogene in prostate carcinoma. , 2017, Future oncology.

[29]  Taylor Jensen,et al.  Epigenetic inactivation of the HOXA gene cluster in breast cancer. , 2006, Cancer research.